
    
      The primary objective of the study is to assess safety and determine the maximum tolerated
      dose of PNK-007 as well as the feasibility of treating at various timepoints following ASCT
      in subjects with multiple myeloma. The secondary objective is to explore the potential
      clinical efficacy by day 90-100 post ASCT.

      Treatment plan includes ASCT followed by PNK-007 which will be administered IV Day 14 post
      ASCT to determine the maximum tolerated dose. Once the IV Day 14 post ASCT. PNK-007 will be
      followed by up to six rhIL-2 injections to support the NK cells expansion in the body.

      Subjects will be followed for up to 12 months post PNK-007.
    
  